Summary: A scalable, CGMP-ready process for viral vector manufacturing that reduces the current 18-20-month development timeline for drug product in half.

Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population.

Summary: The field’s top experts weigh in on the technologies they are working on, including self-amplifying RNA, computer-designed nanoparticles, expanding mRNA processes and...

Summary: Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.

Summary: In this webinar, experts discuss the formulation development challenges, considerations, and potential solutions associated with...

Summary: In this podcast, we will discuss how Catalent is working to simplify the supply chain, develop processes scalable for late-stage and commercial needs, and accelerate timelines for production of clinical materials.

Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.

Summary: During this panel discussion, executives share how their companies adapted to the challenges and what lessons they will take forward to ensure...

Summary: In December 2021, John Chiminski was featured on the expert panel of STAT’s "A Look Ahead at Biotech in 2022" event, which focused on the ongoing battle against the SARS-CoV-2 virus and explored what might be in store for the biotech industry in the years to come.

Summary: On December 13, 2021, EuropaBio hosted the final event of its 25th Anniversary programme with a focus on the story of mRNA.